Infant Data
Results
FDA APPROVED INDICATION
Multivitamin maintenance dosage for infants and children up to 11 years of age receiving parenteral nutrition or in patients in “stress situations” where administration by the IV route is necessary (eg, surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states) to prevent tissue depletion of nutrients.
CONTRAINDICATIONS
Contraindicated in patients with preexisting hypervitaminosis. Product contains aluminum; risk of aluminum toxicity with prolonged administration in the presence of renal impairment in preterm neonates. Vitamin K in Infuvite may antagonize the hypoprothrombinemic response of anticoagulantdrugs. E-Ferol syndrome is associated with polysorbates, which is included in Infuvite.
ADVERSE EFFECTS
Infuvite® Pediatric is administered in intravenous solutions, which may contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Anaphylactic reactions following parenteral multivitamin administration have been reported rarely.
ADMINISTRATION
Should not be given as a direct, undiluted intravenous injection. Add the required dose to not less than 100 mL of dextrose, saline, or similar infusion solutions.
MONITORING
Assess blood vitamin concentrations periodically, particularly in patients on long-term therapy to monitor for vitamin deficiencies or excesses.